Sucrase-isomaltase Deficiency as a Cause of Irritable Bowel Syndrome
Launched by LOVISENBERG DIAKONALE HOSPITAL · Dec 6, 2021
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the connection between a condition called sucrase-isomaltase (SI) deficiency and irritable bowel syndrome (IBS). IBS causes uncomfortable symptoms like stomach pain and bloating, which can significantly affect daily life. Many people with IBS don’t find relief from current treatments, and the researchers believe that SI deficiency might be a reason for this. The study aims to validate a new breath test that could help diagnose SI deficiency without needing a more invasive procedure, like taking a tissue sample from the intestine.
To participate in the trial, you should be between 18 and 65 years old, have a diagnosis of IBS, and be willing to maintain a stable diet throughout the study. Participants will undergo the breath test and follow a specific diet to see if changes in their symptoms relate to their SI activity. The trial is not yet recruiting, but it’s an important step towards understanding how some IBS symptoms might be linked to SI deficiency, potentially leading to better treatment options in the future.
Gender
ALL
Eligibility criteria
- • Validation of the 13C-labelled breath test to diagnose sucrase-isomaltase deficiency (n=40)
- Inclusion Criteria:
- • Signed informed consent
- • BMI 18-30 kg/m2
- • Referred for gastroscopic examination with suspected GI disorder
- Exclusion Criteria:
- • • Unwilling or not capable of signing the informed consent
- • Sucrase-isomaltase deficiency as a cause of symptoms in patients with irritable bowel syndrome (n=80)
- Inclusion Criteria:
- • Signed informed consent
- • BMI 18-30 kg/m2
- • IBS diagnosis according to Rome IV criteria
- Exclusion Criteria:
- • Inflammatory bowel disease, celiac disease or diabetes mellitus
- • Chronic immune diseases affecting the GI-system
- • Unwilling/unable to maintain a stable diet throughout the study period
- • Use of antibiotic treatment for the last 4 weeks
- • Currently on a restrictive diet
About Lovisenberg Diakonale Hospital
Lovisenberg Diakonale Hospital is a reputable healthcare institution located in Oslo, Norway, dedicated to providing high-quality medical care and advancing clinical research. As a clinical trial sponsor, the hospital is committed to fostering innovation in medical treatments and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary team of healthcare professionals and researchers, Lovisenberg Diakonale Hospital prioritizes ethical standards, patient safety, and collaboration with various stakeholders to facilitate groundbreaking studies that address pressing health challenges. The hospital's focus on compassionate care and evidence-based practices positions it as a leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials